Atlas Trials

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

Clinical trial NCT05870423 · RECRUITING

Trial details

NCT number
NCT05870423
Sponsor
Erasmus Medical Center
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Neuroendocrine TumorsPeptide Receptor Radionuclide Therapy
Start date
2022-06-01
Primary completion
2027-01-01
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.